NoCanTher enters clinical study phase

np nocanther clinical study


NoCanTher now enters its final phase with the start of a clinical study aimed at patients with unresectable, locally advanced pancreatic cancer that has not metastasized, who have palliative chemotherapy as the only therapeutic alternative. This population accounts for 20% of patients with pancreatic cancer.

This important milestone marks the culmination of over ten years of scientific work and is one of the last phases of the NoCanTher project. The study will be led from Spain and carried out at two sites - Vall d'Hebron Institute of Oncology (Barcelona) and Hospital Universitario de Fuenlabrada (Madrid). 


Read the institutional press releases from Vall d'Hebron Institute of Oncology, lead of the study, and from IMDEA Nanociencia, coordinator of the project.